The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mosolov S.N.

Moskovskiĭ NII psikhiatrii Roszdrava

Smulevich A.B.

Sechenov First Moscow State Medical University of Ministry of health of the Russia, Moscow, Russia

Neznanov N.G.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.P. Pavlova;
Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva;
fakul'tet psikhiatrii Universiteta shtata Pensil'vaniia (SShA)

Tochilov V.A.

Meditsinskaia akademiia im. I.I. Mechnikova, Sankt-Peterburg

Andreev B.V.

Sankt-Peterburgskiĭ gosudarstvennyĭ universitet, Gatchinskaia oblastnaia psikhiatricheskaia bol'nitsa

Avedisova A.S.

Serbsky Federal Medical Research Center of Psychiatry and Narcology

Bardenshteĭn L.M.

Moskovskiĭ gosudarstvennyĭ stomatologicheskiĭ meditsinskiĭ universitet

Gurovich I.Ia.

Moskovskiĭ NII psikhiatrii;
psikhonevrologicheskiĭ dispanser #13, Moskva

Reznik A.M.

Gosudarstvennyĭ institut usovershenstvovaniia vracheĭ Ministerstva oborony RF, Moskva

Zharkova N.B.

Éli Lilli Vostok SA, Moskva 10. Issledovatel'skie laboratorii Éli Lilli, Indianapolis, SShA

Marteni F.

Issledovatel'skie laboratorii Éli Lilli, Indianapolis, SShA

The use mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial

Authors:

Mosolov S.N., Smulevich A.B., Neznanov N.G., Tochilov V.A., Andreev B.V., Avedisova A.S., Bardenshteĭn L.M., Gurovich I.Ia., Reznik A.M., Zharkova N.B., Marteni F.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(7): 16‑23

Read: 1006 times

Download PDF (RU)
Contact the author
Table of contents

THE USE MGLU2/3 RECEPTORS AS A NEW APPROACH TO TREAT SCHIZOPHRENIA: RESULTS OF A RANDOMIZED DOUBLE-BLIND TRIAL
THE USE MGLU2/3 RECEPTORS AS A NEW APPROACH TO TREAT SCHIZOPHRENIA: RESULTS OF A RANDOMIZED DOUBLE-BLIND TRIAL

To cite this article:

Mosolov SN, Smulevich AB, Neznanov NG, et al. . The use mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(7):16‑23. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
Analysis of cognitive status in patients with different noso­logies and clinical variants of very late mani­festing schi­zophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
Portopulmonary hype­rtension. Journal of Respiratory Medi­cine. 2025;(2):39-44
Abstract:

Glutamate neurotransmission has been considered as one of pathogenetic factors of schizophrenia though all antipsychotics widely used in modern psychiatric practice are dopamine antagonists. LY2140023 is a selective agonist for metabotropic glutamate 2/3 (mGlu2/3) receptors with antipsychotic effect. In the present study, we have assessed clinical efficacy of LY2140023 in patients with schizophrenia compared to the control group receiving olanzapine in a randomized double-blind placebo-controlled trial. The statistically significant reduction of positive and negative symptoms measured with the PANSS (p<0.001) was observed for both antipsychotics at week 4 of treatment compared to placebo. The treatment with LY2140023 was safe and well-tolerated; treated patients did not differ from the placebo group by hyperprolactinemia and extrapyramidal symptoms, and weight gain. The results suggest that the agonist for 2/3 (mGlu2/3) receptors has antipsychotic properties and provides a new, alternative to dopamine agonists, method for pharmacotherapy of schizophrenia.

Keywords:

schizophrenia
treatment
agonist metabotropic glutamate 2/3 (mGlu2/3) receptors

Authors:

Mosolov S.N.

Moskovskiĭ NII psikhiatrii Roszdrava

Smulevich A.B.

Sechenov First Moscow State Medical University of Ministry of health of the Russia, Moscow, Russia

Neznanov N.G.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.P. Pavlova;
Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva;
fakul'tet psikhiatrii Universiteta shtata Pensil'vaniia (SShA)

Tochilov V.A.

Meditsinskaia akademiia im. I.I. Mechnikova, Sankt-Peterburg

Andreev B.V.

Sankt-Peterburgskiĭ gosudarstvennyĭ universitet, Gatchinskaia oblastnaia psikhiatricheskaia bol'nitsa

Avedisova A.S.

Serbsky Federal Medical Research Center of Psychiatry and Narcology

Bardenshteĭn L.M.

Moskovskiĭ gosudarstvennyĭ stomatologicheskiĭ meditsinskiĭ universitet

Gurovich I.Ia.

Moskovskiĭ NII psikhiatrii;
psikhonevrologicheskiĭ dispanser #13, Moskva

Reznik A.M.

Gosudarstvennyĭ institut usovershenstvovaniia vracheĭ Ministerstva oborony RF, Moskva

Zharkova N.B.

Éli Lilli Vostok SA, Moskva 10. Issledovatel'skie laboratorii Éli Lilli, Indianapolis, SShA

Marteni F.

Issledovatel'skie laboratorii Éli Lilli, Indianapolis, SShA

Close metadata

References:

  1. Mosolov S.N. Shkaly psikhometricheskoi otsenki simptomov shizofrenii i kontseptsiya pozitivnykh i negativnykh rasstroistv. M: Novyi tsvet 2001; 238.
  2. Adler C.M., Malhotra A.K., Elman I. et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiat 1999; 156: 10: 1646-1649.
  3. Aghajanian G.K., Marek G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res 2000; 31: 302-312.
  4. Andreasen N.C., Carpenter W.T. Diagnosis and classification of schizophrenia. Schizophr Bull 1993; 19: 199-214.
  5. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiat 1989; 154: 672-676.
  6. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson`s disease. Trends Neurosci 1990; 13: 272-275.
  7. Cartmell J., Monn J.A., Schoepp D.D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus D-amphetaminemotorbehaviorsinrats. J Pharmacol Exp Ther 1999; 291: 161-170.
  8. Crawford A.M., Beasley C.M., Tollefson G.D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr 1997; 26: 41-54.
  9. Daw N.W., Stein P.S.G., Fox K. The role of NMDA receptors in information processing. Annu Rev Neurosci 1993; 16: 207-222.
  10. Egan M.F., Straub R.E., Goldberg T.E. et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Nat Acad Sci USA 2004; 24: 101: 34: 12604-12609.
  11. Feinberg I. Cortical pruning and the development of schizophrenia. Schizophr Bull 1990; 16: 567-568.
  12. Fleischhacker W.W., Meise U., Gunther V., Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiat Scand Suppl 1994; 382: 11-15.
  13. Flor P.J., Battaglia G., Nicoletti F. et al. Neuroprotective activity of metabotropic glutamate receptor ligands. Adv Exp Med Biol 2002; 513: 197-223.
  14. Gainetdinov R.R., Mohn A.R., Bohn L.M., Caron M.G. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc Natl Acad Sci USA 2001; 25: 10; 98: 20: 11047-11054; The changing roles and targets for animal models of schizophrenia. Biol Psychiat 2001; 1: 50: 11: 845-855. Review. Erratum in: Biol Psychiat 2002; 15: 2; 51: 4: 346.
  15. Goff D.C., Tsai G., Manoach D.S. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiat 1996; 153: 1628-1630.
  16. Guy W. ECDEV Assessment Manual for Psychopharmacology. Revised version. Bethesda MD 1976.
  17. Hamilton M. The Assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55.
  18. Harrison P.J., Owen M.J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003; 1: 361(9355): 417-419. Stefansson H., Sigurdsson E., Steinthorsdottir V. et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 10: 71: 4: 877-892.
  19. Heresco-Levy U.  et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiat 2005; 57: 577-585.
  20. Hu G., Duffy P., Swanson C. et al. The regulation of dopamine transmission by metabotropic glutamate receptors. J Pharmacol Exp Ther 1999; 289: 412-416.
  21. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiat 1991; 148: 10: 1301-1308.
  22. Johnson M.P., Chamberlain M. Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268. Neuropharmacology 2002; 43: 799-808.
  23. Kay S.R., Opler L.A., Fiszbein A. Positive and negative syndrome scale (PANSS) manual, Multi-Health Systems, North Tonawanda. NewYork (USA) 1986.
  24. Kim J.S. et al. Low cerebrospinal glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Letter 1980; 20: 379-382.
  25. Krystal J.H., Karper L.P., Seibyl J.P. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiat 1994; 51: 3: 199-214.
  26. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 1: 9-19.
  27. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6: 4: 312-324.
  28. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000; 23: 3: 223-239.
  29. Meltzer H.Y. Neuropsychopharmacology: The Fifth Generation of Progress. In: K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (eds.). 819-831.
  30. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Reports 1962; 10: 6: 799-812.
  31. Patil T., Zhang L., Martenyi F. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Med 2007; 13: 9: 1102-1107.
  32. Pilowsky L.S., Bressan R.A., Stone J.M. et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiat 2006; 11: 2: 118-119.
  33. Rakic P., Bourgeois J.P., Goldman-Rakic P.S. Synaptic development of the cerebral cortex: implications for learning, memory, and mental illness. Prog Brain Res 1994; 102: 227-243.
  34. Rorick-Kehn L.M. et al. Pharmacological and pharmacokinetic properties of a structurally-novel, potent, selective mGlu2/3 receptor agonist: in vitro characterization of LY404039. J Pharmacol Exp Ther 2007; 321: 308-317.
  35. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 2001; 299: 12-20.
  36. Siddiqui O., Ali M.W. A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts. J Biopharm Stat 1998; 8: 4: 545-563.
  37. Simpson G.M., Angus I.W.S. A rating scale for extrapiramide side effects. Acta Psychiat Scand 1970; 46 (Suppl): 212: 11-18.
  38. Stefansson H., Sigurdsson E., Steinthorsdottir V. et al. Neuroregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 10: 71: 877-892.
  39. Svensson L., Zhang J., Johannessen K., Engel J.A. Effect of local infusion of glutamate analogues into the nucleus accumbens of rats: an electrochemical and behavioural study. Brain Res 1994; 643: 155-161.
  40. Tamminga C.A., Lahti A.C. The new generation of antipsychotic drugs. Int Clin Psychopharmacol 1996; 11: 73-76.
  41. Von Bohlen O., Dermietzel H.R. Neurotransmitters and Neuromodulators 2002; 285.
  42. Xi Z.X. et al. Modulation of group II metabotropic glutamate receptor signaling by chronic cocaine. J Pharmacol Exp Ther 2002; 303: 608-615.
  43. Zipursky R.B., Lim K.O., Sullivan E.V. et al. Widespread cerebral grey matter volume deficits in schizophrenia. Arch Gen Psychiat 1992; 49: 195-205.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.